BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 28416753)

  • 1. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
    Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
    Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
    van Hooren L; Sandin LC; Moskalev I; Ellmark P; Dimberg A; Black P; Tötterman TH; Mangsbo SM
    Eur J Immunol; 2017 Feb; 47(2):385-393. PubMed ID: 27873300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.
    Hu M; Peng S; He Y; Qin M; Cong X; Xing Y; Liu M; Yi Z
    Oncotarget; 2015 Jun; 6(17):15348-61. PubMed ID: 25915156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
    Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
    Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of Amaryllidaceae alkaloids haemanthamine and haemanthidine on cell cycle progression and apoptosis in p53-negative human leukemic Jurkat cells.
    Havelek R; Seifrtova M; Kralovec K; Bruckova L; Cahlikova L; Dalecka M; Vavrova J; Rezacova M; Opletal L; Bilkova Z
    Phytomedicine; 2014 Mar; 21(4):479-90. PubMed ID: 24182986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lycorine inhibits the growth and metastasis of breast cancer through the blockage of STAT3 signaling pathway.
    Wang J; Xu J; Xing G
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):771-779. PubMed ID: 28910973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
    Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
    J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
    Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest.
    Li Y; Liu J; Tang LJ; Shi YW; Ren W; Hu WX
    Oncol Rep; 2007 Feb; 17(2):377-84. PubMed ID: 17203177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry.
    Liu R; Cao Z; Tu J; Pan Y; Shang B; Zhang G; Bao M; Zhang S; Yang P; Zhou Q
    Pigment Cell Melanoma Res; 2012 Sep; 25(5):630-8. PubMed ID: 22781316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo.
    Chen S; Liang L; Wang Y; Diao J; Zhao C; Chen G; He Y; Luo C; Wu X; Zhang Y
    Mol Med Rep; 2015 Nov; 12(5):6727-37. PubMed ID: 26300071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.
    Wu L; Wu MO; De la Maza L; Yun Z; Yu J; Zhao Y; Cho J; de Perrot M
    Oncotarget; 2015 May; 6(14):12468-80. PubMed ID: 25980578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity.
    Cao Z; Yu D; Fu S; Zhang G; Pan Y; Bao M; Tu J; Shang B; Guo P; Yang P; Zhou Q
    Toxicol Lett; 2013 Apr; 218(2):174-85. PubMed ID: 23376478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lycorine induces cell death in MM by suppressing Janus Kinase/signal transducer and activator of transcription via inducing the expression of SOCS1.
    Jin Z; Zhou S; Zhang Y; Ye H; Jiang S; Yu K; Ma Y
    Biomed Pharmacother; 2016 Dec; 84():1645-1653. PubMed ID: 27847203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
    Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
    Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antitumor activity of lycorine in renal cell carcinoma ACHN cell line and its mechanism].
    Huang YQ; Zhang YM; Jin Z; Li XZ; Wang CS; Xu K; Huang P; Liu CX
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):857-62. PubMed ID: 27320892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.